@incollection{,
	
					
					
					F5A7D7B49487BF24F14CE43F3E164C20
				,
	author={{Mona M.Salem} and {Usama AA Sharaf ElDin} and {Dina OAbdulazim} and {Cairo University}},
	journal={{Global Journal of Medical Research}},
	journal={{GJMR}}2249-46180975-588810.34257/GJMR,
	address={Cambridge, United States},
	publisher={Global Journals Organisation}1952747
}

@incollection{b0,
	
	
		,
	title={{Curbing the Diabetes Pandemic: The Need for Global Policy Solutions}}
		,
	author={{
			F BHu
		} and {
			ASatija
		} and {
			JManson
		}}
		
		
	
	
		,
	journal={{JAMA}}
		
			313
			23
			
			,
	year={2015 Jun 16}
		
	

}

@incollection{b1,
	
	
		,
	title={{}}
	
	
		,
	journal={{Diabetes Mellitus -epidemiology. World health organization Global report on diabetes}}
		
			,
	year={2016}
		
	

}

@incollection{b2,
	
	
		,
	title={{Clinical Credence-SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease}}
		,
	author={{
			J RIngelfinger
		} and {
			CJRosen
		}}
		
	
	
		,
	journal={{N Engl J Med}}
		
			,
	year={2019 Apr 14}
		
	

}

@incollection{b3,
	
	
		,
	title={{Diabetes mellitus, fasting glucose, and risk of cause-specific death}}
		,
	author={{
			SRao Kondapally Seshasai
		} and {
			SKaptoge
		} and {
			AThompson
		} and {
			DiAngelantonio
		} and {
			EGao
		} and {
			PSarwar
		} and {
			N
		}}
		
		
		
		
		
		
	
	
		,
	journal={{N Engl J Med}}
		
			,
	year={2011 Mar 3}
		
	

}

@incollection{b4,
	
	
		,
	title={{Impact of diabetes mellitus on life expectancy and healthadjusted life expectancy in Canada}}
		,
	author={{
			LLoukine
		} and {
			CWaters
		} and {
			B CChoi
		} and {
			JEllison
		}}
		
		
		
	
	
		,
	journal={{Popul Health Metr}}
		
			10
			7
			,
	year={2012}
		
	

}

@incollection{b5,
	
	
		,
	title={{The worldwide epidemic of diabetic retinopathy}}
		,
	author={{
			YZheng
		} and {
			MHe
		} and {
			NCongdon
		}}
		
		
	
	
		,
	journal={{Indian J Ophthalmol}}
		
			60
			5
			
			,
	year={2012 Sep-Oct}
		
	

}

@incollection{b6,
	
	
		,
	title={{Epidemiology of diabetes and diabetes-related complications}}
		,
	author={{
			Ad1Deshpande
		} and {
			MHarris-Hayes
		} and {
			MSchootman
		}}
		
		
	
	
		,
	journal={{Phys Ther}}
		
			88
			11
			
			,
	year={2008 Nov}
		
	

}

@incollection{b7,
	
	
		,
	title={{Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy}}
		,
	author={{
			S DCandrilli
		} and {
			K LDavis
		} and {
			H JKan
		} and {
			M ALucero
		} and {
			MRousculp
		}}
		
		
		
		
	
	
		,
	journal={{J Diabetes Complications}}
		
			5
			
			,
	year={2007 Sep-Oct; 21}
		
	

}

@incollection{b8,
	
	
		,
	title={{Chronic renal failure in non-insulin dependent diabetes mellitus. A population-based study in}}
		,
	author={{
			L LHumphry
		} and {
			D JBallard
		} and {
			P PFrohnert
		} and {
			C PChu
		} and {
			O'fallon
		} and {
			W MPalumbo
		} and {
			PJ
		}}
		
		
		
		
		
		
	
	
		,
	journal={{Ann Intern Med}}
		
			111
			
			,
	year={1989}
		
	

}

@incollection{b9,
	
	
		,
	title={{Diabetic nephropathy: etiologic and therapeutic considerations}}
		,
	author={{
			RDefronzo
		}}
	
	
		,
	journal={{Diabetes Rev}}
		
			3
			
			,
	year={1995}
		
	

}

@incollection{b10,
	
	
		,
	title={{Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors}}
		,
	author={{
			G ANichols
		} and {
			T AHillier
		} and {
			J RErbey
		} and {
			JBrown
		}}
		
		
		
	
	
		,
	journal={{Diabetes Care}}
		
			24
			9
			
			,
	year={2001 Sep}
		
	

}

@incollection{b11,
	
	
		,
	title={{Molecular mechanisms linking diabetes to the accelerated development of atherosclerosis}}
		,
	author={{
			M GZeadin
		} and {
			C IPetlura
		} and {
			GWerstuck
		}}
		
		
	
	
		,
	journal={{Can J Diabetes}}
		
			37
			
			,
	year={2013}
		
	

}

@incollection{b12,
	
	
		,
	title={{Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes}}
		,
	author={{
			RChen
		} and {
			BOvbiagele
		} and {
			WFeng
		}}
		
		
	
	
		,
	journal={{Am J Med Sci}}
		
			351
			4
			
			,
	year={2016 Apr}
		
	

}

@book{b13,
	
	
		,
	title={{Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus with That of Heart Failure}}
		,
	author={{
			MPacker
		}}
		
			,
	year={2017 Oct 17}
		
	

}

@incollection{b14,
	
	
		,
	title={{Maiese K New Insights for Oxidative Stress and Diabetes Mellitus}}
	
	
		,
	journal={{Oxid Med Cell Longev}}
		
			875961
			,
	year={2015. 2015}
		
	

}

@book{b15,
	
	
		,
	author={{
			WCai
		} and {
			X MDuan
		} and {
			YLiu
		} and {
			JYu
		} and {
			Y LTang
		} and {
			Z LLiu
		}}
		
		
		
		
		
		,
	title={{Uric Acid Induces Endothelial Dysfunction by Activating the HMGB1/RAGE Signaling Pathway}}
				
	

}

@incollection{b16,
	
	
		,
	title={{}}
	
	
		,
	journal={{Biomed Res Int}}
		
			4391920
			,
	year={2017. 2017}
		
	

}

@incollection{b17,
	
	
		,
	title={{Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans}}
		,
	author={{
			J FList
		} and {
			JWhaley
		}}
		
	
	
		,
	journal={{Kidney Int Suppl}}
		
			
			,
	year={2011 Mar; (120}
		
	

}

@incollection{b18,
	
	
		,
	title={{The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus}}
	
	
		,
	journal={{N Engl J Med}}
		
			329
			
			,
	year={1993}
		
	

}

@incollection{b19,
	
	
		,
	title={{Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33)}}
	
	
		,
	journal={{Lancet}}
		
			352
			
			,
	year={1998}
		
		
			UK Prospective Diabetes Study (UKPDS) Group
		
	

}

@incollection{b20,
	
	
		,
	title={{Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a metaanalysis of randomised controlled trials}}
		,
	author={{
			K KRay
		} and {
			S RSeshasai
		} and {
			SWijesuriya
		} and {
			RSivakumaran
		} and {
			SNethercott
		} and {
			DPreiss
		}}
		
		
		
		
		
	
	
		,
	journal={{Lancet}}
		
			373
			
			,
	year={2009}
		
	

}

@incollection{b21,
	
	
		,
	title={{Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)}}
	
	
		,
	journal={{Lancet}}
		
			352
			
			,
	year={1998}
		
		
			UK Prospective Diabetes Study (UKPDS) Group
		
	

}

@incollection{b22,
	
	
		,
	title={{Consensus statement by the American Association Of Clinical Endocrinologists and American College Of Endocrinology on the comprehensive type 2 diabetes management algorithm -2018 executive summary}}
		,
	author={{
			A JGarber
		} and {
			M JAbrahamson
		} and {
			J IBarzilay
		} and {
			LBlonde
		} and {
			Z TBloomgarden
		} and {
			M ABush
		}}
		
		
		
		
		
	
	
		,
	journal={{Endocr Pract}}
		
			24
			1
			
			,
	year={2018 Jan}
		
	

}

@book{b23,
	
	
		,
	title={{Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential. Ther Adv Chronic Dis}}
		,
	author={{
			MRøder
		}}
		
			,
	year={2018 Jan}
			9
			
		
	

}

@incollection{b24,
	
	
		,
	title={{Defronzo RAE mpagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus}}
		,
	author={{
			CTriplitt
		} and {
			CSolis-Herrera
		} and {
			ECersosimo
		} and {
			MAbdul-Ghani
		}}
		
		
		
	
	
		,
	journal={{Expert Opin Pharmac other}}
		
			16
			18
			
			,
	year={2015}
		
	

}

@incollection{b25,
	
	
		,
	title={{Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy}}
		,
	author={{
			MWakisaka
		} and {
			TNagao
		}}
		
	
	
		,
	journal={{Glycobiology}}
		
			,
	year={2017 May 23}
		
	

}

@incollection{b26,
	
	
		,
	title={{The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine}}
		,
	author={{
			R FFurchgott
		} and {
			JZawadzki
		}}
		
	
	
		,
	journal={{Nature}}
		
			288
			
			,
	year={1980}
		
	

}

@incollection{b27,
	
	
		,
	title={{Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent}}
		,
	author={{
			DRoy
		} and {
			MPerreault
		} and {
			AMarette
		}}
		
		
	
	
		,
	journal={{Am J Physiol}}
		
			274
			4
			
			,
	year={1998}
		
	
	,
	note={Pt 1}

}

@book{b28,
	
	
		,
	title={{Caveolin-1 is required for vascular endothelial insulin uptake}}
		,
	author={{
			HWang
		} and {
			A XWang
		} and {
			EJBarrett
		}}
		
		
		
	

}

@incollection{b29,
	
	
		,
	title={{}}
	
	
		,
	journal={{Am J Physiol Endocrinol Metab}}
		
			300
			1
			
			,
	year={2011}
		
	

}

@incollection{b30,
	
	
		,
	title={{The endothelium in diabetes: its role in insulin access and diabetic complications}}
		,
	author={{
			C MKolka
		} and {
			RBergman
		}}
		
	
	
		,
	journal={{Rev Endocr Metab Disord}}
		
			,
	year={2013 Mar}
		
	

}

@incollection{b31,
	
	
		,
	title={{Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus}}
		,
	author={{
			S MShenouda
		} and {
			MEWidlansky
		} and {
			KChen
		} and {
			GXu
		} and {
			MHolbrook
		} and {
			C ETabit
		}}
		
		
		
		
		
	
	
		,
	journal={{Circulation}}
		
			124
			4
			
			,
	year={2011}
		
	

}

@incollection{b32,
	
	
		,
	title={{Targeting endothelial dysfunction in vascular complications associated with diabetes}}
		,
	author={{
			ASharma
		} and {
			P NBernatchez
		} and {
			JDe Haan
		}}
		
		
	
	
		,
	journal={{Int J Vasc Med}}
		
			,
	year={201210. 1155/2012/750126}
		
	

}

@incollection{b33,
	
	
		,
	title={{+)/H(+) exchanger in the regulation of platelet activation and paradoxical effects of cariporide}}
		,
	author={{
			H BChang
		} and {
			XGao
		} and {
			RNepomuceno
		} and {
			SHu
		} and {
			SunDna
		}}
		
		
		
		
	
	
		,
	journal={{Exp Neurol}}
		
			272
			
			,
	year={2015 Oct}
		
	

}

@incollection{b34,
	
	
		,
	title={{Nicotinamide effects oxidative burst activity of neutrophils in patients with poorly controlled type 2 diabetes mellitus}}
		,
	author={{
			ZOsar
		} and {
			TSamanci
		} and {
			G YDemirel
		} and {
			TDamci
		} and {
			HIlkova
		}}
		
		
		
		
	
	
		,
	journal={{Exp Diabesity Res}}
		
			,
	year={2004}
		
	

}

@book{b35,
	
	
		,
	title={{}}
		,
	author={{
			Apr-Jun
		}}
		
			5
			
		
	

}

@incollection{b36,
	
	
		,
	title={{The role of NADPH oxidases in diabetic cardiomyopathy}}
		,
	author={{
			S SHansen
		} and {
			EAasum
		} and {
			AHafstad
		}}
		
		
	
	
		,
	journal={{Biochim Biophys Acta}}
		
			,
	year={2017 Jul 25}
		
	

}

@incollection{b37,
	
	
		,
	title={{Beneficial effects of fenofibric acid on over expression of extracellular matrix components, cox-2, and impairment of endothelial permeability associated with diabetic retinopathy}}
		,
	author={{
			SRoy
		} and {
			DKim
		} and {
			CHernandez
		} and {
			RSimo
		} and {
			SRoy
		}}
		
		
		
		
	
	
		,
	journal={{Exp Eye Res}}
		
			140
			
			,
	year={2015}
		
	

}

@incollection{b38,
	
	
		,
	title={{12/15-Lipoxygenase-derived lipid metabolites induce retinal endothelial cell barrier dysfunction: Contribution of NADPH oxidase}}
		,
	author={{
			AOthman
		} and {
			SAhmad
		} and {
			SMegyerdi
		}}
		
		
	
	
		,
	journal={{PLoS One}}
		
			8
			e57254
			,
	year={2013}
		
	

}

@incollection{b39,
	
	
		,
	title={{The worldwide epidemic of diabetic retinopathy}}
		,
	author={{
			YZheng
		} and {
			MHe
		} and {
			NCongdon
		}}
		
		
	
	
		,
	journal={{Indian J Ophthalmol}}
		
			60
			5
			
			,
	year={2012 Sep-Oct}
		
	

}

@incollection{b40,
	
	
		,
	title={{Inflammation and the pathogenesis of diabetic nephropathy}}
		,
	author={{
			JWada
		} and {
			HMakino
		}}
		
	
	
		,
	journal={{Clin Sci}}
		
			124
			3
			
			,
	year={2013 Feb}
		
	

}

@incollection{b41,
	
	
		,
	title={{High glucose induction of DNAbinding activity of the transcription factor NF-?B in patients with diabetic nephropathy}}
		,
	author={{
			BYang
		} and {
			AHodgkinson
		} and {
			P JOates
		} and {
			B AMillward
		} and {
			ADemaine
		}}
		
		
		
		
	
	
		,
	journal={{Biochim. Biophys. Acta}}
		
			1782
			
			,
	year={2008}
		
	

}

@incollection{b42,
	
	
		,
	title={{Role of high glucose-induced nuclear factor-?B activation in monocyte chemo attractant protein-1 expression by mesangial cells}}
		,
	author={{
			HHa
		} and {
			M RYu
		} and {
			Y JChoi
		} and {
			MKitamura
		} and {
			HLee
		}}
		
		
		
		
	
	
		,
	journal={{J. Am. Soc. Nephrol}}
		
			13
			
			,
	year={2002}
		
	

}

@incollection{b43,
	
	
		,
	title={{High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-? B-dependent}}
		,
	author={{
			C WPark
		} and {
			J HKim
		} and {
			J HLee
		} and {
			Y SKim
		} and {
			H JAhn
		} and {
			YSShin
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetologia}}
		
			43
			
			,
	year={2000}
		
	

}

@incollection{b44,
	
	
		,
	title={{Oxidative stress in diabetic nephropathy}}
		,
	author={{
			NKashihara
		} and {
			YHaruna
		} and {
			V KKondeti
		} and {
			YKanwar
		}}
		
		
		
	
	
		,
	journal={{Curr Med Chem}}
		
			17
			
			,
	year={2010}
		
	

}

@incollection{b45,
	
	
		,
	title={{Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study}}
		,
	author={{
			D IJalal
		} and {
			C JRivard
		} and {
			R JJohnson
		} and {
			D MMaahs
		} and {
			KMcfann
		} and {
			MRewers
		} and {
			JSnell-Bergeon
		}}
		
		
		
		
		
		
	
	
		,
	journal={{Nephrol Dial Transplant}}
		
			25
			6
			
			,
	year={2010 Jun}
		
	

}

@book{b46,
	
	
		,
	title={{High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care}}
		,
	author={{
			L HFicociello
		} and {
			E TRosolowsky
		} and {
			M ANiewczas
		} and {
			N JMaselli
		} and {
			J MWeinberg
		} and {
			AAschengrau
		} and {
			J HEckfeldt
		} and {
			R CStanton
		} and {
			A TGalecki
		} and {
			DoriaAWarram
		} and {
			J HKrolewski
		} and {
			A
		}}
		
		
		
		
		
		
		
		
		
		
		
		
			,
	year={2010 Jun}
			33
			
		
	

}

@incollection{b47,
	
	
		,
	title={{Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study}}
		,
	author={{
			PHovind
		} and {
			PRossing
		} and {
			LTarnow
		} and {
			R JJohnson
		} and {
			HParving
		}}
		
		
		
		
	
	
		,
	journal={{Diabetes}}
		
			58
			7
			
			,
	year={2009 Jul}
		
	

}

@incollection{b48,
	
	
		,
	title={{Uric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population}}
		,
	author={{
			DYan
		} and {
			YTu
		} and {
			FJiang
		} and {
			JWang
		} and {
			RZhang
		} and {
			XSun
		} and {
			TWang
		} and {
			SWang
		} and {
			YBao
		} and {
			CHu
		} and {
			WJia
		}}
		
		
		
		
		
		
		
		
		
		
	
	
		,
	journal={{PLoS One}}
		
			10
			6
			e0129797
			,
	year={2015 Jun 1}
		
	

}

@incollection{b49,
	
	
		,
	title={{AMD-Annals Study Group. Serum Uric Acid and Risk of CKD in Type 2 Diabetes}}
		,
	author={{
			SDe Cosmo
		} and {
			FViazzi
		} and {
			APacilli
		} and {
			CGiorda
		} and {
			ACeriello
		} and {
			SGentile
		} and {
			GRusso
		} and {
			M CRossi
		} and {
			ANicolucci
		} and {
			PGuida
		} and {
			DFeig
		} and {
			R JJohnson
		} and {
			RPontremoli
		}}
		
		
		
		
		
		
		
		
		
		
		
		
	
	
		,
	journal={{Clin J Am Soc Nephrol}}
		
			10
			11
			
			,
	year={2015 Nov 6}
		
	

}

@incollection{b50,
	
	
		,
	title={{Serum Uric Acid as a Risk Factor for Chronic Kidney Disease in a Japanese Community -The Hisayama Study}}
		,
	author={{
			KTakae
		} and {
			MNagata
		} and {
			JHata
		} and {
			NMukai
		} and {
			YHirakawa
		} and {
			DYoshida
		} and {
			HKishimoto
		} and {
			KTsuruya
		} and {
			TKitazono
		} and {
			YKiyohara
		} and {
			TNinomiya
		}}
		
		
		
		
		
		
		
		
		
		
	
	
		,
	journal={{Circ J}}
		
			80
			8
			
			,
	year={2016 Jul 25}
		
	

}

@incollection{b51,
	
	
		,
	title={{Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial}}
		,
	author={{
			J AUdell
		} and {
			D LBhatt
		} and {
			EBraunwald
		} and {
			M ACavender
		} and {
			OMosenzon
		} and {
			PGSteg
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetes Care}}
		
			38
			
			,
	year={2015}
		
	

}

@incollection{b52,
	
	
		,
	title={{DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury}}
		,
	author={{
			EunLee
		} and {
			JKim
		} and {
			JELee
		} and {
			M HSong
		} and {
			H KGhee
		} and {
			J YKang
		} and {
			Y S
		}}
		
		
		
		
		
		
	
	
		,
	journal={{Lab Invest}}
		
			,
	year={2016 May}
		
	

}

@incollection{b53,
	
	
		,
	title={{DPP4 inhibition improves functional outcome after renal ischemiareperfusion injury}}
		,
	author={{
			L LGlorie
		} and {
			AVerhulst
		} and {
			VMatheeussen
		} and {
			LBaerts
		} and {
			JMagielse
		} and {
			NHermans
		}}
		
		
		
		
		
	
	
		,
	journal={{Am J Physiol Renal Physiol}}
		
			303
			
			,
	year={2012}
		
	

}

@incollection{b54,
	
	
		,
	title={{Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors}}
		,
	author={{
			J JHolst
		} and {
			C FDeacon
		}}
		
	
	
		,
	journal={{Diabetologia}}
		
			48
			
			,
	year={2005}
		
	

}

@incollection{b55,
	
	
		,
	title={{Diabetes, hypertension and chronic kidney disease progression: Role of DPP4}}
		,
	author={{
			RNistala
		} and {
			VSavin
		}}
		
	
	
		,
	journal={{Am J Physiol Renal Physiol}}
		
			312
			4
			
			,
	year={2017 Apr 1}
		
	

}

@incollection{b56,
	
	
		,
	title={{What do we know about the secretion and degradation of incretin hormones?}}
		,
	author={{
			CDeacon
		}}
	
	
		,
	journal={{Regul Pept}}
		
			128
			2
			
			,
	year={2005}
		
	

}

@incollection{b57,
	
	
		,
	title={{let it cut or cut it down}}
		,
	author={{
			MDe
		} and {
			IKorom
		} and {
			SVan
		} and {
			D J
		} and {
			ScharpeSCd26
		}}
		
		
		
		
	
	
		,
	journal={{Immunol Today}}
		
			20
			
			,
	year={1999}
		
	

}

@incollection{b58,
	
	
		,
	title={{Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system}}
		,
	author={{
			CKlemann
		} and {
			LWagner
		} and {
			MStephan
		} and {
			VonHorsten
		} and {
			S
		}}
		
		
		
		
	
	
		,
	journal={{Clin Exp Immunol}}
		
			185
			1
			
			,
	year={2016. Jul}
		
	

}

@incollection{b59,
	
	
		,
	title={{Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome}}
		,
	author={{
			DLamers
		} and {
			SFamulla
		} and {
			NWronkowitz
		} and {
			SHartwig
		} and {
			SLehr
		} and {
			D MOuwens
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetes}}
		
			60
			
			,
	year={2011}
		
	

}

@incollection{b60,
	
	
		,
	title={{Zorec RHypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes}}
		,
	author={{
			H HChowdhury
		} and {
			JVelebit
		} and {
			NRadi?
		} and {
			VFran?i?
		} and {
			MKreft
		}}
		
		
		
		
	
	
		,
	journal={{J Diabetes Res}}
		
			7481470
			,
	year={2016. 2016}
		
	

}

@incollection{b61,
	
	
		,
	title={{Sell HShedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells}}
		,
	author={{
			DRöhrborn
		} and {
			JEckel
		}}
		
	
	
		,
	journal={{FEBS Lett}}
		
			,
	year={2014 Nov 3}
		
	

}

@incollection{b62,
	
	
		,
	title={{Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule}}
		,
	author={{
			A CGirardi
		} and {
			B CDegray
		} and {
			TNagy
		} and {
			DBiemesderfer
		} and {
			PAronson
		}}
		
		
		
		
	
	
		,
	journal={{J Biol Chem}}
		
			276
			
			,
	year={2001}
		
	

}

@incollection{b63,
	
	
		,
	title={{Dipeptidyl peptidase IV inhibition downregulates Na+ -H+ exchanger NHE3 in rat renal proximal tubule}}
		,
	author={{
			A CGirardi
		} and {
			L EFukuda
		} and {
			L VRossoni
		} and {
			GMalnic
		} and {
			Reboucas N A
		}}
		
		
		
		
	
	
		,
	journal={{Am J Physiol Renal Physiol}}
		
			294
			
			,
	year={2008}
		
	

}

@incollection{b64,
	
	
		,
	title={{Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules}}
		,
	author={{
			AAroor
		} and {
			MZuberek
		} and {
			CDuta
		} and {
			AMeuth
		} and {
			JRSowers
		} and {
			AWhaley-Connell
		}}
		
		
		
		
		
		pii: E780
	
	
		,
	journal={{Int J Mol Sci}}
		
			17
			5
			,
	year={2016 May 20}
		
	

}

@incollection{b65,
	
	
		,
	title={{Renal tubule albumin transport}}
		,
	author={{
			MGekle
		}}
	
	
		,
	journal={{Annu Rev Physiol}}
		
			67
			
			,
	year={2005}
		
	

}

@incollection{b66,
	
	
		,
	title={{Binding of monoclonal antibodies to glomerular endothelium, slit membranes, and epithelium after in vivo injection. Localization of antigens and bound IgGs by immunoelectron microscopy}}
		,
	author={{
			GDekan
		} and {
			AMiettinen
		} and {
			ESchnabel
		} and {
			MGFarquhar
		}}
		
		
		
	
	
		,
	journal={{Am J Pathol}}
		
			137
			
			,
	year={1990}
		
	

}

@incollection{b67,
	
	
		,
	title={{DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy}}
		,
	author={{
			M LAlter
		} and {
			IOtt
		} and {
			W KTsuprykov
		} and {
			OSharkovska
		} and {
			YKrause-Relle
		} and {
			K
		}}
		
		
		
		
		
	
	
		,
	journal={{Kidney Blood Press Res}}
		
			36
			
			,
	year={2012}
		
	

}

@incollection{b68,
	
	
		,
	title={{Effect of Saxagliptin on renal outcomes in the SAVOR-TIMI 53 Trial}}
		,
	author={{
			OMosenzon
		} and {
			GLeibowitz
		} and {
			DLBhatt
		} and {
			ACahn
		} and {
			BHirshberg
		} and {
			CWei
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetes Care}}
		
			40
			
			,
	year={2017}
		
	

}

@incollection{b69,
	
	
		,
	title={{Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS}}
		,
	author={{
			J HCornel
		} and {
			G LBakris
		} and {
			SStevens
		} and {
			MR, Alvarsson
		} and {
			ABaxw
		} and {
			L MChuang
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetes Care}}
		
			39
			
			,
	year={2016}
		
	

}

@incollection{b70,
	
	
		,
	title={{Alogliptin after acute coronary syndrome in patients with type 2 diabetes}}
		,
	author={{
			W BWhite
		} and {
			C PCannon
		} and {
			S RHeller
		} and {
			S ENissen
		} and {
			R MBergenstal
		} and {
			G LBakris
		}}
		
		
		
		
		
	
	
		,
	journal={{NEngl J Med}}
		
			369
			
			,
	year={2013}
		
	

}

@incollection{b71,
	
	
		,
	title={{Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: The randomized MARLINA-T2D trial}}
		,
	author={{
			P HGroop
		} and {
			M ECooper
		} and {
			VPerkovic
		} and {
			BHocher
		} and {
			KKanasaki
		} and {
			MHaneda
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetes Obes Metab}}
		
			19
			
			,
	year={2017}
		
	

}

@book{b72,
	
	
		,
	title={{MLinagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care}}
		,
	author={{
			P HGroop
		} and {
			M ECooper
		} and {
			VPerkovic
		} and {
			AEmser
		} and {
			H JWoerle
		} and {
			VonEynatten
		}}
		
		
		
		
		
		
			,
	year={2013 Nov}
			36
			
		
	

}

@book{b73,
	
	
		,
	title={{Linagliptin-mediated DPP-4}}
		,
	author={{
			KKanasaki
		} and {
			SShi
		} and {
			MKanasaki
		} and {
			JHe
		} and {
			TNagai
		} and {
			YNakamura
		}}
		
		
		
		
		
		
			,
	year={2014 Jun}
			63
			
		
	

}

@incollection{b74,
	
	
		,
	title={{Interactions of DPP-4 and integrin ?1 influences endothelial-to-mesenchymal transition}}
		,
	author={{
			SShi
		} and {
			S PSrivastava
		} and {
			MKanasaki
		} and {
			JHe
		} and {
			MKitada
		} and {
			TNagai
		}}
		
		
		
		
		
	
	
		,
	journal={{Kidney Int}}
		
			88
			3
			
			,
	year={2015 Sep}
		
	

}

@book{b75,
	
	
		,
	title={{Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation. Sci Rep}}
		,
	author={{
			S
		}}
		
			,
	year={2016 Jul 6}
			6
			29393
			,
	address={Lee C S 1, 2, 3, Kim Y G 4, Cho HJ 1, 2, 4, Park J 1, 2, 4, Jeong H 1, Lee S E 1, 2, 4, Lee}
		
	

}

@incollection{b76,
	
	
		,
	title={{Protective Effects of Dipeptidyl Peptidase-4 Inhibitors on Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes}}
		,
	author={{
			Y RChung
		} and {
			S WPark
		} and {
			J WKim
		} and {
			JKim
		}}
		
		
		
	
	
		,
	journal={{Retina}}
		
			36
			12
			,
	year={2016 Dec}
		
	

}

@incollection{b77,
	
	
		,
	title={{Serum CXCL10 and CXCL12 chemokine levels are associated with the severity of coronary artery disease and coronary artery occlusion}}
		,
	author={{
			V TFerdousie
		} and {
			M MMohammadi
		} and {
			GHassanshahi
		} and {
			HKhorramdelazad
		} and {
			S KFalahati-Pour
		} and {
			MMirzaei
		}}
		
		
		
		
		
	
	
		,
	journal={{Int J Cardiol}}
		
			233
			
			,
	year={2017}
		
	

}

@incollection{b78,
	
	
		,
	title={{Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease}}
		,
	author={{
			M NDarisipudi
		} and {
			O PKulkarni
		} and {
			S GSayyed
		} and {
			MRyu
		} and {
			AMigliorini
		} and {
			CSagrinati
		}}
		
		
		
		
		
	
	
		,
	journal={{Am J Pathol}}
		
			179
			
			,
	year={2011}
		
	

}

@incollection{b79,
	
	
		,
	title={{SDF-1 is both necessary and sufficient to promote proliferative retinopathy}}
		,
	author={{
			J MButler
		} and {
			S MGuthrie
		} and {
			MKoc
		} and {
			AAfzal
		} and {
			SCaballero
		} and {
			H LBrooks
		}}
		
		
		
		
		
	
	
		,
	journal={{J Clin Invest}}
		
			115
			
			,
	year={2005}
		
	

}

@incollection{b80,
	
	
		,
	title={{Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes}}
		,
	author={{
			R ADefronzo
		} and {
			MHompesch
		} and {
			SKasichayanula
		} and {
			XLiu
		} and {
			YHong
		} and {
			MPfister
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetes Care}}
		
			36
			
			,
	year={2013}
		
	

}

@incollection{b81,
	
	
		,
	title={{Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome}}
		,
	author={{
			E JBommel
		} and {
			M HMuskiet
		} and {
			LTonneijck
		} and {
			M HKramer
		} and {
			MNieuwdorp
		} and {
			D HVan Raalte
		} and {
			Sglt2
		}}
		
		
		
		
		
		
	
	
		,
	journal={{Clin J Am Soc Nephrol}}
		
			12
			4
			
			,
	year={2017 Apr 3}
		
	

}

@incollection{b82,
	
	
		,
	title={{SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria}}
		,
	author={{
			YChino
		} and {
			YSamukawa
		} and {
			SSakai
		} and {
			YNakai
		} and {
			JYamaguchi
		} and {
			TNakanishi
		}}
		
		
		
		
		
	
	
		,
	journal={{Biopharm Drug Dispos}}
		
			35
			
			,
	year={2014}
		
	

}

@incollection{b83,
	
	
		,
	title={{Fructose and uric acid in diabetic nephropathy}}
		,
	author={{
			PBjornstad
		} and {
			M ALanaspa
		} and {
			TIshimoto
		} and {
			TKosugi
		} and {
			SKume
		} and {
			DJalal
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetologia}}
		
			,
	year={2015 Sep}
		
	

}

@incollection{b84,
	
	
		,
	title={{Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension}}
		,
	author={{
			MCristóbal-García
		} and {
			F EGarcía-Arroyo
		} and {
			ETapia
		} and {
			HOsorio
		} and {
			A SArellano-Buendía
		} and {
			MMadero
		}}
		
		
		
		
		
	
	
		,
	journal={{Oxid Med Cell Longev}}
		
			535686
			,
	year={2015. 2015}
		
	

}

@incollection{b85,
	
	
		,
	title={{Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease}}
		,
	author={{
			E-SRyu
		} and {
			M JKim
		} and {
			H-SShin
		} and {
			Y HJang
		} and {
			H SChoi
		} and {
			JoI
		}}
		
		
		
		
		
	
	
		,
	journal={{Am J Physiol Renal Physiol}}
		
			304
			
			,
	year={2013}
		
	

}

@incollection{b86,
	
	
		,
	title={{Wuling San protects kidney dysfunction by inhibiting renalTLR4/MyD88 signaling and NLRP3 inflamma some activation in high fructose-induced hyperuricemic mice}}
		,
	author={{
			Yang Y 1
		} and {
			Zhang D M 1
		} and {
			J H 1Liu
		} and {
			Hu L S 2, Xue Q C 1
		} and {
			XDing
		}}
		
		
		
		
	
	
		,
	journal={{J Ethnopharmacol}}
		
			169
			
			,
	year={2015 Jul 1}
		
	

}

@incollection{b87,
	
	
		,
	title={{Living forever and dying in the attempt}}
		,
	author={{
			LHayflick
		}}
	
	
		,
	journal={{Experimental Gerontology}}
		
			38
			
			,
	year={2003}
		
	

}

@incollection{b88,
	
	
		,
	title={{Hyperglycemia causes cellular senescence via a SGLT2-and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy}}
		,
	author={{
			KKitada
		} and {
			DNakano
		} and {
			HOhsaki
		} and {
			HHitomi
		} and {
			TMinamino
		} and {
			JYatabe
		}}
		
		
		
		
		
	
	
		,
	journal={{J Diabetes Complications}}
		
	

}

@incollection{b89,
	
	
		,
	title={{Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?}}
		,
	author={{
			UPanchapakesan
		} and {
			KPegg
		} and {
			SGross
		} and {
			M GKomala
		} and {
			HMudaliar
		} and {
			JForbes
		}}
		
		
		
		
		
	
	
		,
	journal={{PLoS One}}
		
			8
			2
			e54442
			,
	year={2013}
		
	

}

@incollection{b90,
	
	
		,
	title={{Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis}}
		,
	author={{
			AOjima
		} and {
			TMatsui
		} and {
			YNishino
		} and {
			NNakamura
		} and {
			SYamagishi
		}}
		
		
		
		
	
	
		,
	journal={{Horm Metab Res}}
		
			47
			9
			
			,
	year={2015 Aug}
		
	

}

@incollection{b91,
	
	
		,
	title={{Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice}}
		,
	author={{
			NTerami
		} and {
			DOgawa
		} and {
			HTachibana
		} and {
			THatanaka
		} and {
			JWada
		} and {
			ANakatsuka
		}}
		
		
		
		
		
	
	
		,
	journal={{PLoS One}}
		
			9
			6
			e100777
			,
	year={2014 Jun 24}
		
	

}

@incollection{b92,
	
	
		,
	title={{Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids}}
		,
	author={{
			CCicerchi
		} and {
			NLi
		} and {
			JKratzer
		} and {
			GGarcia
		} and {
			C ARoncal-Jimenez
		} and {
			KTanabe
		}}
		
		
		
		
		
	
	
		,
	journal={{FASEB J}}
		
			28
			8
			
			,
	year={2014 Aug}
		
	

}

@incollection{b93,
	
	
		,
	title={{The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors}}
		,
	author={{
			JphWilding
		}}
	
	
		,
	journal={{Metabolism}}
		
			63
			
			,
	year={2014}
		
	

}

@incollection{b94,
	
	
		,
	title={{Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes}}
		,
	author={{
			CWanner
		} and {
			S EInzucchi
		} and {
			J MLachin
		} and {
			DFitchett
		} and {
			MVon Eynatten
		} and {
			MMattheus
		}}
		
		
		
		
		
	
	
		,
	journal={{N Engl J Med}}
		
			,
	year={2016 Jul 28}
		
	

}

@incollection{b95,
	
	
		,
	title={{Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy}}
		,
	author={{
			B MBrenner
		} and {
			M ECooper
		} and {
			DDe Zeeuw
		} and {
			W FKeane
		} and {
			W EMitch
		} and {
			H HParving
		} and {
			GRemuzzi
		} and {
			S MSnapinn
		} and {
			ZZhang
		} and {
			S; Renaal StudyShahinfar
		} and {
			Investigators
		}}
		
		
		
		
		
		
		
		
		
		
	
	
		,
	journal={{N Engl J Med}}
		
			345
			12
			
			,
	year={2001 Sep 20}
		
	

}

@incollection{b96,
	
	
		,
	title={{Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy}}
		,
	author={{
			HYamout
		} and {
			GLBakris
		}}
		
	
	
		,
	journal={{Nat Rev Nephrol}}
		
			12
			10
			
			,
	year={2016 Oct}
		
	

}

@incollection{b97,
	
	
		,
	title={{Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors}}
		,
	author={{
			RGrempler
		} and {
			LThomas
		} and {
			MEckhardt
		} and {
			FHimmelsbach
		} and {
			ASauer
		} and {
			D ESharp
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetes Obes Metab}}
		
			14
			1
			
			,
	year={2012 Jan}
		
	

}

@incollection{b98,
	
	
		,
	title={{Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus}}
		,
	author={{
			D ZCherney
		} and {
			B APerkins
		} and {
			NSoleymanlou
		} and {
			MMaione
		} and {
			VLai
		} and {
			ALee
		}}
		
		
		
		
		
	
	
		,
	journal={{Circulation}}
		
			129
			5
			
			,
	year={2014 Feb 4}
		
	

}

@incollection{b99,
	
	
		,
	title={{Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation}}
		,
	author={{
			LUthman
		} and {
			ABaartscheer
		} and {
			BBleijlevens
		} and {
			C ASchumacher
		} and {
			JwtFiolet
		} and {
			AKoeman
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetologia}}
		
			61
			3
			
			,
	year={2018 Mar}
		
	

}

@incollection{b100,
	
	
		,
	title={{The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects}}
		,
	author={{
			RVettor
		} and {
			S EInzucchi
		} and {
			PFioretto
		}}
		
		
	
	
		,
	journal={{Diabetologia}}
		
			60
			3
			
			,
	year={2017 Mar}
		
	

}

@incollection{b101,
	
	
		,
	title={{Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits}}
		,
	author={{
			ABaartscheer
		} and {
			C ASchumacher
		} and {
			R CWüst
		} and {
			J WFiolet
		} and {
			G JStienen
		} and {
			RCoronel
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetologia}}
		
			60
			3
			
			,
	year={2017 Mar}
		
	

}

@incollection{b102,
	
	
		,
	title={{Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration}}
		,
	author={{
			MSkrti?
		} and {
			G KYang
		} and {
			B APerkins
		} and {
			NSoleymanlou
		} and {
			YLytvyn
		} and {
			MVon Eynatten
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetologia}}
		
			57
			12
			
			,
	year={2014 Dec}
		
	

}

@incollection{b103,
	
	
		,
	title={{Dapagliflozin a glucoseregulating drug with diuretic properties in subjects with type 2 diabetes}}
		,
	author={{
			LambersHeerspink
		} and {
			H JDe Zeeuw
		} and {
			DWie
		} and {
			LLeslie
		} and {
			BList
		} and {
			J
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetes Obes Metab}}
		
			15
			9
			
			,
	year={2013 Sep}
		
	

}

@incollection{b104,
	
	
		,
	title={{Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes}}
		,
	author={{
			D ZCherney
		} and {
			B APerkins
		} and {
			NSoleymanlou
		} and {
			FXiao
		} and {
			JZimpelmann
		} and {
			H JWoerle
		}}
		
		
		
		
		
	
	
		,
	journal={{Kidney Int}}
		
			86
			5
			
			,
	year={2014 Nov}
		
	

}

@incollection{b105,
	
	
		,
	title={{Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects}}
		,
	author={{
			H JHeerspink
		} and {
			MDesai
		} and {
			MJardine
		} and {
			DBalis
		} and {
			GMeininger
		} and {
			VPerkovic
		}}
		
		
		
		
		
	
	
		,
	journal={{J Am Soc Nephrol}}
		
			28
			1
			
			,
	year={2017 Jan}
		
	

}

@incollection{b106,
	
	
		,
	title={{Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network metaanalysis}}
		,
	author={{
			HTang
		} and {
			GLi
		} and {
			YZhao
		} and {
			FWang
		} and {
			E WGower
		} and {
			LShi
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetes Obes Metab}}
		
			,
	year={2018 Jan 25}
		
	

}

@book{b107,
	
	
		,
	title={{}}
		,
	author={{
			BNeal
		} and {
			VPerkovic
		} and {
			K WMahaffey
		} and {
			De
		}}
		
		
		
		
	

}

@book{b108,
	
	
		,
	title={{Canagliflozin and Cardiovascular and Renal Events in Type 2}}
		,
	author={{
			DZeeuw
		} and {
			GFulcher
		}}
		
		
	

}

@incollection{b109,
	
	
		,
	title={{}}
	
	
		,
	journal={{Diabetes. N Engl J Med}}
		
			377
			7
			
			,
	year={2017 Aug 17}
		
	

}

@book{b110,
	
	
		,
	title={{Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation}}
		,
	author={{
			K WMahaffey
		} and {
			BNeal
		} and {
			VPerkovic
		} and {
			DDe Zeeuw
		} and {
			GFulcher
		}}
		
		
		
		
		
			,
	year={2018 Jan 23}
			137
			
		
	

}

@incollection{b111,
	
	
		,
	title={{Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes}}
		,
	author={{
			S DWiviott
		} and {
			IRaz
		} and {
			M PBonaca
		} and {
			OMosenzon
		} and {
			E TKato
		}}
		
		
		
		
	
	
		,
	journal={{N Engl J Med}}
		
			380
			4
			
			,
	year={2019 Jan 24}
		
	

}

@incollection{b112,
	
	
		,
	title={{Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Subanalysis from DECLARETIMI-58 Trial}}
		,
	author={{
			RhmFurtado
		} and {
			M PBonaca
		} and {
			IRaz
		} and {
			T AZelniker
		} and {
			OMosenzon
		}}
		
		
		
		
	
	
		,
	journal={{Circulation}}
		
			,
	year={2019 Mar 18}
		
	

}

@incollection{b113,
	
	
		,
	title={{ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways}}
		,
	author={{
			S RDas
		} and {
			B MEverett
		} and {
			K KBirtcher
		} and {
			J MBrown
		} and {
			W TCefalu
		}}
		
		
		
		
	
	
		,
	journal={{J Am Coll Cardiol}}
		
			72
			
			,
	year={2018. 2018}
		
	

}

@incollection{b114,
	
	
		,
	title={{Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy}}
		,
	author={{
			VPerkovic
		} and {
			M JJardine
		} and {
			BNeal
		} and {
			SBompoint
		} and {
			HjlHeerspink
		}}
		
		
		
		
	
	
		,
	journal={{N Engl J Med}}
		
			,
	year={2019 Apr 14}
		
	

}

@incollection{b115,
	
	
		,
	title={{Effects of dapagliflozin on development and progression of kidney diseasein patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial}}
		,
	author={{
			OMosenzon
		} and {
			S DWiviott
		} and {
			ACahn
		} and {
			ARozenberg
		} and {
			IYanuv
		}}
		
		
		
		
	
	
		,
	journal={{Lancet Diabetes Endocrinol}}
		
			,
	year={2019 Published Online June 9. 2019}
		
	

}

@incollection{b116,
	
	
		,
	title={{Are reactive oxygen species still the basis for diabetic complications?}}
		,
	author={{
			DiMarco
		} and {
			EJha
		} and {
			J CSharma
		} and {
			AWilkinson-Berka
		} and {
			J L
		} and {
			Jandeleit-Dahm K ADe Haan
		}}
		
		
		
		
		
	
	
		,
	journal={{Clin Sci}}
		
			129
			2
			
			,
	year={2015 Jul}
		
	

}

@book{b117,
	
	
		,
	title={{Should We Change the Therapeutic Algorithm of Type 2 Diabetes Based on Accumulating Evidence?}}
		
	

}

@incollection{b118,
	
	
		,
	title={{The Nrf2 pathway in the progression of renal disease}}
		,
	author={{
			CZoja
		} and {
			ABenigni
		} and {
			GRemuzzi
		}}
		
		
	
	
		,
	journal={{Nephrol Dial Transplant}}
		
			29
			1
			
			,
	year={2014 Feb}
		
	
	,
	note={Suppl}

}

@incollection{b119,
	
	
		,
	title={{Activation of Nrf2 signaling by natural products-can it all eviate diabetes?}}
		,
	author={{
			MMatzinger
		} and {
			KFischhuber
		} and {
			EHHeiss
		}}
		
		
		S0734-9750
	
	
		,
	journal={{Biotechnol Adv}}
		
			17
			
			,
	year={2017 Dec 28}
		
	

}

@incollection{b120,
	
	
		,
	title={{Ceradini DJThe Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus}}
		,
	author={{
			J ADavid
		} and {
			W JRifkin
		} and {
			PRabbani
		}}
		
		
	
	
		,
	journal={{J Diabetes Res}}
		
			4826724
			,
	year={2017. 2017}
		
	

}

@incollection{b121,
	
	
		,
	title={{Natural Nrf2 activators in diabetes}}
		,
	author={{
			Jiménez-Osorio A SGonzález-Reyes
		} and {
			SPedraza-Chaverri
		} and {
			J
		}}
		
		
	
	
		,
	journal={{Clin Chim Acta}}
		
			448
			
			,
	year={2015 Aug 25}
		
	

}

@incollection{b122,
	
	
		,
	title={{Protective Effects of Berberine on Renal Injury in Streptozotocin (STZ)-Induced Diabetic Mice}}
		,
	author={{
			XZhang
		} and {
			HHe
		} and {
			DLiang
		} and {
			YJiang
		} and {
			WLiang
		} and {
			Z HChi
		}}
		
		
		
		
		
	
	
		,
	journal={{Int J Mol Sci}}
		
			17
			8
			,
	year={2016 Aug 12}
		
	

}

@incollection{b123,
	
	
		,
	title={{Momordica charantia polysaccharides mitigate the progression of STZ induced diabetic nephropathy in rats}}
		,
	author={{
			MRaish
		} and {
			AAhmad
		} and {
			B LJan
		} and {
			K MAlkharfy
		} and {
			M AAnsari
		} and {
			KMohsin
		}}
		
		
		
		
		
	
	
		,
	journal={{Int J Biol Macromol}}
		
			91
			
			,
	year={2016 Oct}
		
	

}

@incollection{b124,
	
	
		,
	title={{Sinomenine alleviates high glucose-induced renal glomerular endothelial hyperpermeability by inhibiting the activation of RhoA/ROCK signaling pathway}}
		,
	author={{
			QYin
		} and {
			YXia
		} and {
			GWang
		}}
		
		
	
	
		,
	journal={{Biochem Biophys Res Commun}}
		
			477
			4
			
			,
	year={2016 Sep 2}
		
	

}

@incollection{b125,
	
	
		,
	title={{Effect of broccoli sprouts on insulin resistance in type 2 diabetic patients: a randomized double-blind clinical trial}}
		,
	author={{
			ZBahadoran
		} and {
			MTohidi
		} and {
			PNazeri
		} and {
			MMehran
		} and {
			FAzizi
		} and {
			PMirmiran
		}}
		
		
		
		
		
	
	
		,
	journal={{Int J Food Sci Nutr}}
		
			63
			7
			
			,
	year={2012 Nov}
		
	

}

@incollection{b126,
	
	
		,
	title={{Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients}}
		,
	author={{
			PBrasnyó
		} and {
			G AMolnár
		} and {
			MMohás
		} and {
			LMarkó
		} and {
			BLaczy
		} and {
			JCseh
		}}
		
		
		
		
		
	
	
		,
	journal={{Br J Nutr}}
		
			106
			3
			
			,
	year={2011 Aug}
		
	

}

@incollection{b127,
	
	
		,
	title={{Effects of resveratrol in patients with type 2 diabetes mellituson skeletal muscle SIRT1 expression and energy expenditure}}
		,
	author={{
			K PGoh
		} and {
			H YLee
		} and {
			D PLau
		} and {
			WSupaat
		} and {
			Y HChan
		} and {
			AFKoh
		}}
		
		
		
		
		
	
	
		,
	journal={{Int J Sport Nutr Exerc Metab}}
		
			24
			1
			
			,
	year={2014 Feb}
		
	

}

@incollection{b128,
	
	
		,
	title={{Administration of resveratrol for 5 wk has no effect on glucagonlike peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial}}
		,
	author={{
			S SThazhath
		} and {
			TWu
		} and {
			M JBound
		} and {
			H LChecklin
		} and {
			SStandfield
		} and {
			KJones
		}}
		
		
		
		
		
	
	
		,
	journal={{Am J Clin Nutr}}
		
			103
			1
			
			,
	year={2016 Jan}
		
	

}

@incollection{b129,
	
	
		,
	title={{One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease}}
		,
	author={{
			JTomé-Carneiro
		} and {
			MGonzálvez
		} and {
			MLarrosa
		} and {
			M JYáñez-Gascón
		} and {
			F JGarcía-Almagro
		} and {
			J ARuiz-Ros
		}}
		
		
		
		
		
	
	
		,
	journal={{Am J Cardiol}}
		
			110
			3
			
			,
	year={2012 Aug 1}
		
	

}

@book{b130,
	
	
		,
	title={{One-year supplementation with a grape extract containing resveratrol modulates}}
		,
	author={{
			JTomé-Carneiro
		} and {
			MLarrosa
		} and {
			M JYáñez-Gascón
		} and {
			ADávalos
		} and {
			JGil-Zamorano
		} and {
			MGonzálvez
		}}
		
		
		
		
		
		
	

}

@incollection{b131,
	
	
		,
	title={{}}
	
	
		,
	journal={{Pharmacol Res}}
		
			72
			
			,
	year={2013 Jun}
		
	

}

@incollection{b132,
	
	
		,
	title={{Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial}}
		,
	author={{
			SBo
		} and {
			VPonzo
		} and {
			GCiccone
		} and {
			AEvangelista
		} and {
			FSaba
		} and {
			IGoitre
		}}
		
		
		
		
		
	
	
		,
	journal={{Pharmacol Res}}
		
			111
			
			,
	year={2016 Sep}
		
	

}

@incollection{b133,
	
	
		,
	title={{Howe P R Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus}}
		,
	author={{
			R HWong
		} and {
			R SNealon
		} and {
			AScholey
		}}
		
		
	
	
		,
	journal={{Nutr Metab Cardiovasc Dis}}
		
			26
			5
			
			,
	year={2016 May}
		
	

}

@incollection{b134,
	
	
		,
	title={{Acute Resveratrol Consumption Improves Neurovascular Coupling Capacity in Adults with Type 2 Diabetes Mellitus}}
		,
	author={{
			R HWong
		} and {
			DRaederstorff
		} and {
			PRHowe
		}}
		
		
		pii: E425
	
	
		,
	journal={{Nutrients}}
		
			8
			7
			,
	year={2016 Jul 12}
		
	

}

@incollection{b135,
	
	
		,
	title={{Tatsuno IResveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Patients With Type 2 Diabetes Mellitus}}
		,
	author={{
			HImamura
		} and {
			TYamaguchi
		} and {
			DNagayama
		} and {
			ASaiki
		} and {
			KShirai
		}}
		
		
		
		
	
	
		,
	journal={{Int Heart J}}
		
			58
			4
			
			,
	year={2017 Aug 3}
		
	

}

@incollection{b136,
	
	
		,
	title={{Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study}}
		,
	author={{
			PUsharani
		} and {
			A AMateen
		} and {
			M UNaidu
		} and {
			Y SRaju
		} and {
			NChandra
		}}
		
		
		
		
	
	
		,
	journal={{Drugs R D}}
		
			9
			4
			
			,
	year={2008}
		
	

}

@incollection{b137,
	
	
		,
	title={{Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-? and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study}}
		,
	author={{
			P1Khajehdehi
		} and {
			MPakfetrat
		} and {
			KJavidnia
		} and {
			FAzad
		} and {
			LMalekmakan
		} and {
			M HNasab
		}}
		
		
		
		
		
	
	
		,
	journal={{Scand J Urol Nephrol}}
		
			45
			5
			
			,
	year={2011 Nov}
		
	

}

@book{b138,
	
	
		,
	title={{Curcumin extract for prevention of type 2 diabetes. Diabetes Care}}
		,
	author={{
			SChuengsamarn
		} and {
			SRattanamongkolgul
		} and {
			RLuechapudiporn
		} and {
			CPhisalaphong
		} and {
			SJirawatnotai
		}}
		
		
		
		
		
			,
	year={2012 Nov}
			35
			
		
	

}

@incollection{b139,
	
	
		,
	title={{Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes}}
		,
	author={{
			YanNa L X 1
		} and {
			CuiJiang S 1
		}}
		
	
	
		,
	journal={{Biomed Environ Sci}}
		
			,
	year={2014 Nov}
		
	

}

@incollection{b140,
	
	
		,
	title={{Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus}}
		,
	author={{
			RNeerati P 1, Devde
		} and {
			AGangi
		}}
		
	
	
		,
	journal={{Phytother Res}}
		
			28
			12
			
			,
	year={2014 Dec}
		
	

}

@incollection{b141,
	
	
		,
	title={{Curcuminoids exert glucoselowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebocontrolled trial}}
		,
	author={{
			Na L X 1
		} and {
			YLi
		} and {
			H ZPan
		} and {
			X LZhou
		} and {
			D JSun
		} and {
			MMeng
		} and {
			X XLi
		} and {
			CHSun
		}}
		
		
		
		
		
		
		
	
	
		,
	journal={{Mol Nutr Food Res}}
		
			,
	year={2013 Sep}
		
	

}

@incollection{b142,
	
	
		,
	title={{A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)}}
		,
	author={{
			M JDavies
		} and {
			D'alessio
		} and {
			D AFradkin
		} and {
			JKernan
		} and {
			W NMathieu
		} and {
			C
		}}
		
		
		
		
		
	
	
		,
	journal={{Diabetologia}}
		
			61
			12
			
			,
	year={2018. 2018 Dec}
		
	
	,
	note={Management of hyperglycaemia in type 2 diabetes}

}

@incollection{b143,
	
	
		,
	title={{Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm -2019 Executive Summary}}
		,
	author={{
			AlanJGarber
		} and {
			MartinJAbrahamson
		} and {
			JoshuaIBarzilay
		} and {
			LawrenceBlonde
		}}
		
		
		
	
	
		,
	journal={{Endocrine Practice}}
		
			25
			1
			
			,
	year={2019. January 2019}
		
	

}

@incollection{b144,
	
	
		,
	title={{The role of mannose-binding lectin in health and disease}}
		,
	author={{
			MTurner
		}}
	
	
		,
	journal={{Mol Immunol}}
		
			40
			7
			
			,
	year={2003 Nov}
		
	

}

@incollection{b145,
	
	
		,
	title={{Increased levels of mannanbinding lectin in type 1 diabetic patients with incipient and overt nephropathy}}
		,
	author={{
			MSaraheimo
		} and {
			CForsblom
		} and {
			T KHansen
		} and {
			A MTeppo
		} and {
			JFagerudd
		}}
		
		
		
		
	
	
		,
	journal={{Diabetologia}}
		
			48
			1
			
			,
	year={2005 Jan}
		
	

}

@incollection{b146,
	
	
		,
	title={{Complement activation in patients with diabetic nephropathy}}
		,
	author={{
			X QLi
		} and {
			D YChang
		} and {
			MChen
		} and {
			MHZhao
		}}
		
		
		
	
	
		,
	journal={{Diabetes Metab}}
		
			18
			
			,
	year={2018 Apr 16}
		
	

}

@incollection{b147,
	
	
		,
	title={{Du JIncreased serum mannose binding lectin levels are associated with diabetic retinopathy}}
		,
	author={{
			XMan
		} and {
			HZhang
		} and {
			HYu
		} and {
			LMa
		}}
		
		
		
	
	
		,
	journal={{J Diabetes Complications}}
		
	

}

@incollection{b148,
	
	
		,
	title={{High Mannose-Binding Lectin Serum Levels Are Associated with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes}}
		,
	author={{
			QHuang
		} and {
			GShang
		} and {
			HDeng
		} and {
			JLiu
		} and {
			YMei
		}}
		
		
		
		
	
	
		,
	journal={{PLoS One}}
		
			10
			7
			e0130665
			,
	year={2015 Jul 2}
		
	

}

@incollection{b149,
	
	
		,
	title={{Binding Lectin and Diabetic Nephropathy in Type 1 Diabetes}}
		,
	author={{
			S QZhao
		} and {
			HuZmannose
		}}
		
	
	
		,
	journal={{J Clin Lab Anal}}
		
			30
			4
			
			,
	year={2016 Jul}
		
	

}

@incollection{b150,
	
	
		,
	title={{Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes}}
		,
	author={{
			L ZGuan
		} and {
			QTong
		} and {
			JXu
		}}
		
		
	
	
		,
	journal={{PLoS One}}
		
			10
			3
			e0119699
			,
	year={2015 Mar 24}
		
	

}

@incollection{b151,
	
	
		,
	title={{Association between mannose-binding lectin and vascular complications in type 1 diabetes}}
		,
	author={{
			T KHansen
		} and {
			LTarnow
		} and {
			SThiel
		} and {
			RSteffensen
		} and {
			C DStehouwer
		}}
		
		
		
		
	
	
		,
	journal={{Diabetes}}
		
			53
			6
			
			,
	year={2004 Jun}
		
	

}

@incollection{b152,
	
	
		,
	title={{Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study}}
		,
	author={{
			PHovind
		} and {
			T KHansen
		} and {
			LTarnow
		} and {
			SThiel
		} and {
			RSteffensen
		}}
		
		
		
		
	
	
		,
	journal={{Diabetes}}
		
			54
			5
			
			,
	year={2005 May}
		
	

}

@incollection{b153,
	
	
		,
	title={{Clinical Significance of Hemostatic Parameters in the Prediction for Type 2 Diabetes Mellitus and Diabetic Nephropathy}}
		,
	author={{
			LPan
		} and {
			YYe
		} and {
			MWo
		} and {
			DBao
		} and {
			FZhu
		}}
		
		
		
		
	
	
		,
	journal={{Dis Markers}}
		
			5214376
			,
	year={2018 Feb 4. 2018}
		
	

}

@incollection{b154,
	
	
		,
	title={{Association and biomarker potential of elevated serum adiponectin with nephropathy among type 1 and type 2 diabetics: A metaanalysis}}
		,
	author={{
			NPabalan
		} and {
			R ETiongco
		} and {
			J KPandac
		} and {
			N AParagas
		} and {
			S LLasta
		}}
		
		
		
		
	
	
		,
	journal={{PLoS ONE}}
		
			13
			12
			e0208905
		
	

}

@incollection{b155,
	
	
		,
	title={{American Diabetes Association: Standards of medical care in diabetes-2016}}
	
	
		,
	journal={{Diabetes Care}}
		
			
			,
	year={2016}
		
	
	,
	note={Suppl 1}

}

@incollection{b156,
	
	
		,
	title={{10-year follow-up of intensive glucose controlin type 2 diabetes}}
		,
	author={{
			R RHolman
		} and {
			S KPaul
		} and {
			M ABethel
		} and {
			DRMatthews
		} and {
			HawNeil
		}}
		
		
		
		
	
	
		,
	journal={{N Engl J Med}}
		
			359
			
			,
	year={2008}
		
	

}

@incollection{b157,
	
	
		,
	title={{The course of kidney function in type 2 (non-insulindependent) diabetic patients with diabetic nephropathy}}
		,
	author={{
			F SGall M A 1, Nielsen
		} and {
			U MSmidt
		} and {
			HParving
		}}
		
		
	
	
		,
	journal={{Diabetologia}}
		
			36
			10
			
			,
	year={1993 Oct}
		
	

}